Prevalence of childhood cancer survivors increasing
the ONA take:
According to a study published in the journal Cancer Epidemiology, Biomarkers & Prevention, researchers have found that the prevalence of childhood cancer survivors is increasing, and most of those who have survived at least 5 years beyond diagnosis may have at least one comorbidity.
Using nine U.S. Surveillance, Epidemiology, and End Results (SEER) registries and data from the Childhood Cancer Survivor Study (CCSS), researchers estimated that there are 388,501 childhood cancer survivors in the United States, an increase of nearly 60,000 from the previous 2005 National Cancer Institute estimate.
Researchers found that approximately 84% of survivors have survived 5 or more years since diagnosis. The study also showed that about 70% of childhood cancer survivors have a mild or moderate chronic condition and about 32% have a severe, disabling, or life-threatening chronic condition.
The findings suggest that more needs to be done to effectively decrease morbidity burden in childhood cancer survivors, particularly those with neurocognitive dysfunction, self-reported functional impairment, activity limitations, impaired mental health, pain, or anxiety and fear.
Prevalence of childhood cancer survivors is increasing, and those who survived at least 5 years beyond diagnosis have at least one comorbidity.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|